PT-141
10mg
A melanocortin-receptor peptide studied in receptor-binding research models.
Bundle & save
Strength
- Ships in 24 hours
- HPLC & endotoxin verified
- Encrypted checkout
Research details
Areas of research interest
PT-141 is studied for sexual desire and arousal, acting on brain pathways rather than on blood flow. Bremelanotide is the active ingredient in an FDA-approved prescription medicine for low sexual desire in premenopausal women. This research-grade material is not that product and is not for human use.
Overview
PT-141 (bremelanotide) is a synthetic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). It activates melanocortin receptors in the brain, mainly MC4R in the hypothalamus. This central mechanism differs from PDE5 inhibitors, which act on blood flow.
Research summary
Phase 3 trials. The two RECONNECT trials randomized about 1,250 premenopausal women with hypoactive sexual desire disorder to bremelanotide or placebo [1]. Bremelanotide produced statistically significant improvements in sexual desire and reductions in desire-related distress at 24 weeks [1].
Long-term extension. In a 52-week open-label extension, no new safety signals emerged, and improvements in symptoms were sustained [2].
Regulatory status. FDA approved bremelanotide in June 2019. Prescribing information advises against use in people with cardiovascular disease or uncontrolled high blood pressure because of transient blood pressure increases.
References
- 1. Kingsberg SA, et al. Obstet Gynecol. 2019;134(5):899–908. PMID: 31599840
- 2. Simon JA, et al. Obstet Gynecol. 2019;134(5):909–917. PMID: 31599847
For laboratory research use only. Not for human or veterinary use. This product is not a drug, food, cosmetic, or dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.